Time- and Dose-Dependent Neuroprotective Effects

of Sex Steroid Hormones on Inflammatory Cytokines

after a Traumatic Brain Injury by Sarkaki, Ali Reza et al.
Time- and Dose-Dependent Neuroprotective Effects
of Sex Steroid Hormones on Inflammatory Cytokines
after a Traumatic Brain Injury
Ali Reza Sarkaki,1 Mohammad Khaksari Haddad,2 Zahra Soltani,3 Nader Shahrokhi,4 and Mehdi Mahmoodi5
Abstract
Following a traumatic brain injury (TBI), excessive release of proinflammatory cytokines is the major cause of cerebral
edema and neuronal loss. This study was designed to examine changes in concentrations of some proinflammatory
cytokines—including interleukin-1 beta (IL-1b), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-a), and trans-
forming growth factor-beta (TGF-b)—in a rat model of TBI in which the animals were treated with different doses of
estrogen or progesterone 6 and 24 h after the TBI. Adult female rats were divided into 14 groups. Hormones or vehicle
were given intraperitoneally 30min after a moderate TBI was induced by the Marmarou method. The levels of proin-
flammatory cytokines in brain were measured at 6 and 24 h after the TBI. A high dose of estrogen (E2) or a low dose of
progesterone (P1) increased brain levels of IL-1b 52.7% and 79.2% respectively at 6 h after the TBI. By 24h, IL-1b levels
in the brain were 27.5% and 27% lower following administration of estrogen low dose (E1) or E2, respectively. High-dose
administration of progesterone reduced brain levels of IL-6 to 45.9% at 6 h after the TBI, and P1 and E1 treatment
significantly decreased IL-6 levels at 24 h. Brain levels of TNF-a were 72.5% lower at 6 h after the TBI following P2
treatment and 48.5% higher at 24 hrs following treatment with E2. The levels of TGF-b were also 3.37 times higher 24 h
after the TBI following treatment with E1. Both doses of the hormones tested increases TGF-b levels 6 h after the TBI.
Based on our findings, we conclude that progesterone and estrogen influence the levels of proinflammatory cytokines
either at the primary or secondary stages after a TBI. Accordingly, this study suggests a mechanism by which hormones
reduce cerebral edema.
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Introduction
Although intracranial inflammatory responses inducedby a traumatic brain injury (TBI) or brain ischemia play
crucial roles in wound healing processes, they are the leading cause
of secondary brain injuries following a TBI (Morganti-Kossmann
et al., 2002; Rothwell and Hopkins, 1995). Brain contusion-induced
inflammation contributes to these secondary brain injuries (Holmin
andMathiesen, 2000). Brain contusions induce functional disorders
mostly through edema. Experimental studies have shown that un-
controlled brain edema is a major cause of many of the disabilities
and mortalities that accompany TBIs (Stein DG, 2008).
Central nervous system events following a brain trauma occur
during the acute or chronic recovery phases (Morrison et al., 1998).
The acute phase is sub-divided into a primary and secondary step.
In primary step, the injury results from the trauma itself, whereas in
the secondary step, the injury is caused by release of chemical
factors and cytokines. The onset of the chronic recovery phase
depends on the development of the injury and the expression of
important mediators (e.g., cytokines) for tissue reconstruction
(McIntosh et al., 1998; Morrison et al., 1998). Brain edema for-
mation, compression of the blood brain barrier, release of inflam-
matory cytokines and growth factors are among the late responses
to a traumatic injury. A complex cytokine network forms around
the traumatized region within the brain during both the primary and
secondary (late) phases of recovery (Morganti-Kossmann et al.,
2002).
Cytokines like interleukin-1 beta (IL-1b), interleukin 6 (IL-6),
and tumor necrosis factor-alpha (TNF-a) promote inflammatory
responses, whereas cytokines such as interleukin 4 (IL-4) and
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interleukin 10 (IL-10) inhibit inflammatory responses in the central
nervous system (Olsson, 1995). Elevated levels of IL-1b and TNF-a
have been observed in the cerebrospinal fluid of brain parenchyma
tissues following brain traumas (Ross et al., 1994). These increased
levels of these proinflammatory cytokines can clearly intensify the
brain lesions that occur during ischemia, trauma, or cytotoxic brain
injuries (Lawrence et al., 1998). The production of proinflammatory
cytokines after a TBI has been reported in animal models (Taupin
et al., 1993; Woodroofe et al., 1991) and humans (Morganti-
Kossman et al., 1997; Ross et al., 1994).
Central administration of IL-1b leads to brain edema and cell
death (Holmin and Mathiesen, 2000). Therefore, the measurement
of cytokines within the brain aids in the understanding of the in-
flammatory responses induced by TBI. Several studies have shown
that IL-1b, IL-6, and TNF-a are among themainmediators of neural
inflammation (Holmin and Hojeberg, 2004; Morganti-Kossmann
et al., 2002; Rothwell and Hopkins, 1995). Up-regulation of trans-
forming growth factor-beta (TGF-() after a TBI regulates activation
of the brain vessel endothelium (Dore-Duffy et al., 1994; McIntosh
et al., 1998), which in turn prevents the influx of leukocytes across
the blood brain barrier (Fee et al., 2004; Hoffman et al., 2006;
Hussein et al., 2004).
Recent studies indicated that estrogen and progesterone signif-
icantly decrease brain edema and increase functional recovery after
a trauma. For example, edema was not found in female animals
with hyper-progestinemia (Roof et al., 1993). An inverse correla-
tion was observed between levels of progesterone in serum and
brain edema following a TBI (Wright et al., 2001). Our previous
study showed that progesterone and its metabolite allopregnano-
lone are effective in the reduction of brain edema (Ahmad molaie
et al., 2007). The neuroprotective properties of estradiol on brain
ischemia have been observed in female rats (Won et al., 2006).
Estrogen and progesterone can decrease vasogenic edema after
TBIs (Ahmad molaie et al., 2007; Hoffman, 2001). Estrogen and
progesterone reduce brain edema, blood brain barrier permeability,
and intracranial pressure after TBIs (Shahrokhi et al., 2010). Si-
multaneous use of estrogen and progesterone decreased brain
edema and improved neurologic outcomes in an experimental brain
trauma model (Soltani et al., 2009). In previous studies, that re-
search group showed sex steroid hormones reduce neural inflam-
mation. In the present study, to determine the mechanism
underlying the anti-inflammation effects of these hormones, we
measured the levels of proinflammatory cytokines (TGF-b, TNF-a,
IL-6, and IL-1b) after brain trauma induced by the Marmarou
method in ovariectomized rats. We evaluated the effects of estro-
gen and progesterone on the levels of brain cytokines at 6 and 24
hours after the TBI. We used these two time points because cyto-
kine expression changes over the different phases of trauma
(Morganti-Kossmann et al., 2002; Rothwell and Hopkins, 1995),
the inhibitory effects of progesterone on the production of in-
flammatory cytokines is time dependent (He et al., 2004), and the
inhibitory effects of estrogen on IL-1b production occurs over two
steps (Das et al., 2002).
Methods
Animals
This study was conducted in accordance with the guidelines for
animal experiments of Kerman University of Medical Sciences.
The study protocols were approved by the ethical committee (No:
EC/KNRC/87-19) of the University. Mature female Albino N-Mari
rats (weighing 200–250 g) were housed in an air conditioned room
at 22–25C, with a 12-hour light/dark cycle. Animals had free
access to food and water.
Bilateral ovariectomy procedures
The animals were anesthetized using 60mg/kg thiopental in-
traperitonealy (i.p.). The sub-abdominal region was shaved and an
incision of 2 centimeter was created. The skin, fascia, and ab-
dominal muscles were opened, and fats and the intestine were
sheared off until the uterus and its tubes became apparent. Then, the
tube of the uterus and vascular base of the ovaries were twisted by a
4 Cat coot thread around the proximal area and were cut at the distal
area. Finally, 1–2ml of saline solution was poured into the abdo-
men and the muscles and skin were replaced and stitched by 0–2
aught silk suture. The wound was washed with Betadine solution.
To avoid confounds from different effects on estrus cycles, all
experimental animals were ovariectomized (OVX) two weeks be-
fore the experiments (Crandall et al., 2006).
Experimental protocols
Adult female rats were randomly divided into 7 groups consist of
two subgroups. The experimental groups were as follows: 1) sham
surgery group: received no vehicle or drug, 2) TBI group: OVX rats
that underwent brain traumas, 3) vehicle- treated group: OVX rats
that received equal-volume injections of estrogen or progesterone
vehicle (sesame oil containing 1% benzyl alcohol) after the TBI, 4)
E1-treated group: OVX rats that received physiologic doses of 17-b
estradiol (33.3lg/kg), 5) E2-treated group: OVX rats that received
pharmacologic doses of 17-b estradiol (1mg/kg), 6) P1-treated
group: OVX rats that received physiologic doses of progesterone
(1.7mg/kg), 7) P2-treated group: OVX rats that received pharma-
cologic doses of progesterone (8mg/kg). 17-b estradiol or pro-
gesterone were given as a single-dose i.p. 30min after the TBI
(Ahmad molaie et al., 2007; O’Connor et al., 2005). 17-b estradiol,
progesterone, and their vehicles were purchased from Aburaihan
pharmaceuticals (Tehran, Iran).
Brain IL-1b, IL-6, TNF-a, TGF-b, 17b-estradiol, and proges-
terone were measured in all groups at 6 or 24 hours after the TBI.
Diffuse TBI model
All animals were intubated before the TBI. The TBI was a
moderate and diffuse injury based on the Marmarou method
(O’Connor et al., 2005). The TBI induction device was made by the
Department of Physiology of the Kerman University of Medical
Sciences. The protocol was as follows: a 250g weight was dropped
from 2 meters above the head of the anesthetized rat while a metal
disc (stainless steel) 10mm in diameter and 3mm thick was attached
on the animals’ skull. Following induction of the TBI, all rats were
immediately connected to a respiratory pump (TSA animal respi-
ratory compact, Germany). Following restoration of spontaneous
breathing, the intratracheal tube was removed. After recovery, each
rat was housed in an individual cage.
Measurement of brain cytokines and hormones
Rats received an overdose of thiopental (50mg/kg, i.p) 6 or 24
hours after a TBI (Dubal et al., 2001; Holmin and Hojeberg, 2004),
and were perfused intracardially with phosphate buffered saline
(pH = 7.4) for 1min to remove vesicular blood. Then, each brain
was removed quickly and immediately frozen in liquid nitrogen.
The brain was weighed and homogenized in T-PERTM tissue
protein extraction reagent with 0.5% Triton-x100, 150mM NaCl,
50mM tris, and a protease inhibitor cocktail (500mg tissue per 2ml
of the reagent). Following homogenization, samples were shaken
on a shaker (Behdad, Iran) for 90min and then centrifuged (Rotina,
Germany) at 4C and 4000 · g for 15min, and the supernatant was
collected as a homogenate. The protein content of the supernatant
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was estimated using a protein assay reagent kit to ensure an equal
amount of protein from each sample was used for the assay (Taupin
et al., 1993).
ELISA kits for IL-1b, IL-6, TNF-a, TGF-b, 17b-estradiol, and
progesterone were purchased from American BMS and the assays
were performed according to the manufacturer’s guidelines. The
concentrations of the cytokines were quantified as picograms or
nanograms of antigen per milliliter of the supernatant.
Statistical analysis
All quantitative data are expressed as the mean – the standard
error of the mean (SEM). If a repeated measures two-way analysis
of variance (ANOVA) revealed a significant interaction between
the group and time factors, comparisons of changes between groups
or across time were assessed separately by a parametric one-way
ANOVA. One-way ANOVA was used for concentration analyses.
Fisher’s least square difference was employed for ANOVA post-
hoc analysis. Comparisons of changes in cytokines levels at dif-
ferent times were analyzed by independent t-tests. All differences
were considered significant at P < 0.05.
Results
Changes in brain IL-1b levels at 6
and 24 hours after TBI
Because two-way repeated measures ANOVA revealed a sig-
nificant interaction between treatment group and time for IL-1b
(across time P < 0.01, interaction between group and time P < 0.001,
and between group P < 0.001), the results of statistical analysis by
one-way ANOVA are reported here.
Figure 1 shows the effects of different doses of progesterone and
estrogen on the levels of brain IL-1b 6 and 24 hours after TBI. The
brain levels of IL-1b were significantly increased by a high dose of
estrogen (272.7 – 17.8 pg/ml, P< 0.01) or a low dose of progester-
one (319.8– 27.3 pg/ml, P< 0.001) compared to vehicle (178.7–
22.7 pg/ml) at 6 hours after TBI. This level was significantly de-
creased by a high dose (223.6– 30.1 pg/ml) or low dose (224.6–
32.8 pg/ml) of estrogen compared to vehicle at 24 hours after TBI. A
TBI decreased the levels of IL-1b 6 hours later, but conversely
increased IL-1b levels 24 hours later compared to sham surgeries.
Therefore, diffuse TBI decreased brain IL-1b levels in the early
stage but increased these levels in the delayed stage of trauma
(P< 0.01) (fig 2). Significant differences in the vehicle group were
not found 6 and 24 hours after TBI.
Reductions in brain IL-6 levels by sex steroids
Because two-way repeated measures ANOVA revealed a sig-
nificant interaction between treatment group and time for IL-1b
(across time P< 0.01, interaction between group and time P< 0.001,
and between group P< 0.001), the results of statistical analysis by
one-way ANOVA are reported here.
Figure 3 shows the effects of different doses of estrogen or pro-
gesterone on brain IL-6 levels 6 and 24 hours after the TBI. A high
dose of progesterone decreased brain IL-6 levels (340.3– 52.7 pg/ml)
compared to vehicle (629.1– 28.4 pg/ml, P< 0.01) at 6 hours after the
TBI. Brain IL-6 levels significantly differed following high or low
dose progesterone treatments (P< 0.05). These levels decreased
following a low dose of progesterone (852.4– 99.1 pg/ml, P< 0.05)
or a low dose of estrogen (563– 32.7 pg/ml, P<0.001) compared to
vehicle (1073– 46.1 pg/ml) at 24 hours after the TBI. Therefore,
estrogen decreased brain IL-6 levels during the delayed stage of
trauma. TBI increased brain IL-6 levels at 6 hours after the TBI, but
IL-6 levels were conversely lower at 24 hours after the TBI compared
to sham surgeries (P< 0.05) (fig.2). There were no significant dif-
ferences in the vehicle groups 6 and 24 hours after the TBI.
Changes in brain TNF-a levels 6 and 24 hours
after the TBI
Because two-way repeated measures ANOVA revealed a sig-
nificant interaction between treatment group and time for TNF-a
(across time P< 0.001, interaction between group and time P< 0.05,
and between group P< 0.001), the results of statistical analysis by
one way ANOVA are reported here.
Fig. 4 shows the effects of different doses of estrogen or pro-
gesterone on TNF-a levels in the brain 6 and 24 hours after the TBI.
A high dose of progesterone decreased brain TNF-a levels
(80.4 – 0.09 pg/ml) compared to vehicle (287.2 – 42.6 pg/ml), at 6
hours after the TBI (p < 0.01). A high dose of estrogen increased
brain TNF-a levels (902.1 – 248.5 pg/ml) compared to vehicle
FIG. 1. Effects of estrogen and progesterone on brain level of
IL-1b following TBI in OVX female rats (n = 7/ group). IL-1b was
measured at 6 and 24 h post injury. ***P < 0.001as compared to
veh at 6 h post injury. **P< 0.01 as compared to veh at 6 h post
injury.{P< 0.05 as compared to veh at 24 h post injury. Values
represent mean–SEM. Veh: vehicle; E1: physiological dose of
estrogen; E2: pharmacological dose of estrogen; P1 : physiological
dose of progesterone ; P2 :pharmacological dose of progesterone.
FIG. 2. Changes percent of IL-1b, IL-6, TNF-a, and TGF-b
following TBI in OVX female rats compared to sham (n = 7/
group). Cytokines were measured at 6 and 24h post injury. **P<0.01
as compared cytokines groups, at 6 and 24h post injury. *P<0.05 as
compared cytokines groups, at 6 and 24h post injury. Values represent
mean–SEM.
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(607.2 – 46.9 pg/ml, P < 0.05), at 24 hours after the TBI. Brain
TNF-a levels were higher at 6 hours and lower at 24 hours after the
TBI compared to sham surgeries (fig2). After the TBI, the levels of
TNF-a in were higher in the vehicle group at 24 hours compared to
at 6 hours (p < 0.001).
Sex steroids increased brain TGF-b levels after the TBI
Because two-way repeated measures ANOVA revealed a sig-
nificant interaction between treatment group and time for TGF-b
(across time P < 0.001, interaction between group and time
P < 0.001, and between group P < 0.001), the results of statistical
analysis by one way ANOVA are reported here.
Fig. 5 shows the effects of different doses of sex steroids on brain
TGF-b levels at different times. A low dose of estrogen increased
brain TGF-b levels (18.2 – 1.1 ng/ml) compared to vehicle
(P < 0.001) at 6 hours after the TBI, and there was a significant
difference between the group that received a low dose of estrogen
and other groups (P < 0.001). Different doses of estrogen and pro-
gesterone increased brain TGF-b levels compared to vehicle across
time (P< 0.001). These levels were higher at 6 hours but lower at 24
hours after the TBI compared to sham surgeries (P < 0.01)(fig2).
Moreover, these levels decreased in the vehicle group over time
(P < 0.001).
Changes in brain estrogen and progesterone levels
Because two-way repeated measures ANOVA revealed a sig-
nificant interaction between treatment group and time for estradiol
and progesterone (across time P< 0.01, interaction between group
and time P < 0.05, and between group P < 0.001 for estradiol; and
across time P< 0.001, interaction between group and time P < 0.01,
and between group P < 0.001 for progesterone), the results of sta-
tistical analysis by one way ANOVA are reported here.
Fig. 6 and 7 show changes in 17b-estradiol and progesterone
across the different groups in this study 6 and 24 hours after the
TBI. There were no significant differences in the brain levels of
17b-estradiol at the different time points after the TBI. The highest
17b-estradiol level was observed following high dose of estrogen at
6 hours (1619.7 – 484.9 pg/ml) and at 24 hours (608.7– 403 pg/ml)
after the TBI (P< 0.001). The brain 17b-estradiol levels decreased
after injection of estrogen over time (P < 0.001). The levels of
progesterone in the brain significantly decreased over time and
were 27.9 – 2.5 ng/ml at 6 hours and 12.3 – 0.51 ng/ml at 24 hours
after the TBI (P< 0.001) in the vehicle groups. A high dose of
progesterone increased the levels of progesterone in the brain at
both 6 hours (43.6 – 104 ng/ml) and 24 hours (27.7– 306 ng/ml)
after the TBI (P< 0.01).
Discussion
Studies have suggested that sex steroid hormones inhibit the
inflammatory edemas caused by TBI, and provide neuroprotection
FIG. 3. Effects of estrogen and progesterone on brain level of
IL-6 following TBI in OVX female rats (n = 7/group). IL-6 was
measured at 6 and 24 h post injury. **P< 0.01 as compared to veh
at 6 h post injury. {{{P< 0.001 as compared to veh at 24 h post
injury. {P< 0.05 as compared to veh at 24h post injury. Values
represent mean–SEM. Veh: vehicle; E1: physiological dose of
estrogen; E2: pharmacological dose of estrogen; P1 : physiological
dose of progesterone ;P2 : pharmacological dose of progesterone.
FIG. 4. Effects of estrogen and progesterone on brain level of
TNF-a following TBI in OVX female rats (n = 7/group). TNF-a
was measured at 6 and 24 h post injury. **P < 0.01 as compared to
veh at 6 h post injury. ###P< 0.001 as compared vehicle groups, at
6 and 24 h post injury. {P < 0.05 as compared to veh at 24 h post
injury. Values represent mean– SEM. Veh: vehicle; E1: physio-
logical dose of estrogen; E2: pharmacological dose of estrogen;
P1: physiological dose of progesterone; P2: pharmacological dose
of progesterone.
FIG. 5. Effects of estrogen and progesterone on brain level of
TGF-b following TBI in OVX female rats (n = 7/group). TGF-b
was measured at 6 and 24 h post injury. {{{P < 0.001 as compared
to all groups at 24 h post injury. ***P < 0.001 as compared to all
groups at 6 h post injury. ###P < 0.001 as compared vehicle groups,
at 6 and 24 h post injury. Values represent mean –SEM. Veh:
vehicle; E1: physiological dose of estrogen; E2: pharmacological
dose of estrogen; P1: physiological dose of progesterone; P2:
pharmacological dose of progesterone.
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after a TBI. We examined the hypothesis that these sex steroids
inhibit inflammation by influencing cytokine concentrations.
Brain IL-1b levels after the TBI
Our results show that high doses of estrogen and low doses of
progesterone increase brain IL-1b levels in the primary stage of the
acute phase of the injury (i.e., 6 hours after the TBI). Twenty four
hours after the TBI (secondary step), these hormones produced
opposite effects on brain IL-1b levels. These data suggest that the
effects of estrogen and progesterone on the levels of IL-1b are time
and dose dependent. TBIs lead to a 51% decrease in IL-1b during
the primary step of the acute phase of the injury, whereas there
is 1.3 fold increase in IL-1b in the secondary step of the acute phase
of the injury.
Alterations in the levels of cytokines in different models of in-
jury—such as frontal brain ischemia (Taupin et al., 1993), injuries
from fluid-percussion (Fan et al., 1996; Taupin et al., 1993), spinal
cord injury (Streit et al., 1998), and experimental TBIs (McIntosh
et al., 1998; Morrison et al., 1998)—have been reported. The
changes in cytokines level usually start 30 minutes after a brain
injury and continue for at least 24 hours after the trauma. In this
study, we showed decreased levels of IL-1b 6 hours after the TBI in
rats, which is in agreement with the observations of LaMarca et.al.
(2007) in mice after brain ischemia (LaMarca et al., 2007), of
Minami et.al. (1992) in rats after transitional ischemia, and with
those made after brain injuries and TBIs (Bartfai et al., 2007; Jones
et al., 2005a; Konsman et al., 2007). One possible mechanism for
elevated IL-1b levels in the presence of estrogen or progesterone at
6 hours after the TBI could be that we used ineffective dose of these
hormones in this model (Gibson et al., 2005; Holmin and Hojeberg,
2004; Jones et al., 2005a; Lacut et al., 2003). Alternatively, it may
derive from the regulating effects of these hormones on inflam-
matory responses (Cutolo et al., 2006). Several studies have re-
ported that estrogen (Das et al., 2002; Houdeau et al., 2007) or
progesterone (Chen et al., 2008; Gibson et al., 2005; He et al., 2004)
decrease IL-1b levels after a brain injury. The probable reasons for
the discrepancies with the presently reported results may be the
type and severity of the injury, the dose and the treatment regimen
of the hormones, and the type of vehicle used.
On the other hand, decreased production of IL-1b in the presence
of estrogen at 24 hours after trauma occurred concurrently with
induction of its mRNA expression and was followed in turn by the
maximum production of this cytokine (Hans et al., 1999). Whereas
the concentration of IL-1b in patients with higher ICP is more than
those with lower ICP (Shiozaki et al., 2005), inhibition of IL-1b
production prevents the neuronal injury caused by TBI (Lu et al.,
2007). Administration of an IL-1b receptor antagonist following
TBI decreases neuronal inflammation ( Jones et al., 2005b). As
such, we assumed that the altered levels of IL-1b by estrogen at
either dose tested were the mechanism for the anti-inflammatory
action of estrogen and its other neuroprotective effects. The de-
creased levels of IL-1b following estrogen treatment in our model
are consistent with other studies (Das et al., 2002; Houdeau et al.,
2007; Schaefer et al., 2005), and the ineffectiveness of proges-
terone on the levels of IL-1b has been confirmed by a number of
previous researchers ( Jones et al., 2005a). Progesterone presum-
ably exerts its anti-edema effects through other mechanisms
(Gibson et al., 2005; Hoffman et al., 2006; Lenzlinger et al.,
2001). Some studies have indeed proposed that decreasing effects
of progesterone on the levels of IL-1b after a TBI, which is
opposite to the findings of the present study (Chen et al., 2008;
Gibson et al., 2005; He et al., 2004). Moreover, it has been
reported that estrogen in the primary step of the acute phase of the
injury increases but in the next step of the acute phase decreases
the levels of IL-1b, whereas progesterone has only unitary effects
(Das et al., 2002). Therefore, according to the results of our work,
as only estrogen has inhibitory effects on IL-1b, reduced IL-1b
levels is likely the mechanism for the neuroprotective effects of
estrogen either in the primary or secondary steps of an injury,
whereas progesterone is only neuroprotective in the primary step
of the acute phase of recovery after a TBI.
The high concentration of brain b-estradiol in the groups treated
with a high dose of estrogen probably led to the effectiveness of a
high dose of estrogen 6 h after the TBI. The effectiveness of both
FIG. 6. Effects of estrogen administration on brain level of
b-estradiol following TBI in OVX female rats (n = 7/group).
b-estradiol was measured at 6 and 24 h post injury. ***P< 0.001
as compared to veh at 6 h post injury. {{{P < 0.001 as compared to
veh at 24 h post injury. Values represent mean – SEM. Veh: ve-
hicle; E1: physiological dose of estrogen; E2: pharmacological
dose of estrogen; P1: physiological dose of progesterone; P2:
pharmacological dose of progesterone.
FIG. 7. Effect of progesterone administration on brain level of
progesterone following TBI in OVX female rats (n = 7/ group).
Progesterone was measured at 6 and 24 h post injury. ###P< 0.001
as compared vehicle groups, at 6 and 24 h post injury. **P< 0.01 as
compared to veh at 6 h post injury. {{P< 0.01 as compared to veh at
24 h post injury. Values represent mean–SEM. Veh: vehicle; E1:
physiological dose of estrogen; E2: pharmacological dose of es-
trogen; P1: physiological dose of progesterone; P2: pharmacolog-
ical dose of progesterone.
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doses of the hormones at 24h after the TBI is probably related to
brain physiologic concentrations of estrogen, as with progesterone.
Brain IL-6 levels after a TBI
Progesterone reduced IL-6 levels in both the primary step and
secondary step of the acute phase. However, this effect depends on
the dose of progesterone, as only the low dose of estrogen at 24
hours after the TBI decreased the levels of this cytokine. TBI in-
creased the levels of IL-6 2.2 fold in the primary step of the acute
phase of the injury, whereas 24 hours after the TBI, the concen-
tration of this cytokine decreased to about 0.25 fold. Because
progesterone in both the primary and secondary step decreased the
levels of IL-6, it seems that this cytokine has more important role in
the mediation of the anti-inflammatory actions of progesterone
compared to estrogen. IL-6 induces loss of neurons, disturbances in
BBB function, and vascular insufficiency accompanied by severe
neurological disorders (Lenzlinger et al., 2001). The effects of
progesterone in the different phases after a TBI depend on the dose
used. This finding is consistent with the results of other researchers
(Chen et al., 2008; Cutler et al., 2007).Moreover, other studies have
also shown the decreasing effect of estrogen on the level of IL-6
(Hrekova et al., 2002; Jain et al., 2004).
The high concentration of brain progesterone in the group
treated with a high dose of progesterone probably is because it
reduced IL-6 levels 6 h after the TBI. In addition, the effectiveness
of low doses of the hormones at 24 after TBI is probably related to
brain physiologic concentration of brain hormones. A number of
studies have reported opposite effects of estrogen (Crandall et al.,
2006; Jonsson, 2007; Lacut et al., 2003) and progesterone (Crandall
et al., 2006; Lacut et al., 2003) on IL-6 levels. The reasons for these
different results may the type and severity of the injury, the regimen
used for the hormones, and the type of vehicle used.
Brain TNF-a levels after a TBI
We showed that a high dose of progesterone in primary step of
acute phase reduced TNF-a levels. In contrast, during the second-
ary step of the acute phase, progesterone lost its effectiveness and a
high dose of estrogen increased the levels of TNF-a. Because it has
been reported that rising TNF-a levels during the acute phase of
recovery is harmful (Sullivan et al., 1999), the decreasing effects
of progesterone on this cytokine may prevent the deleterious effects
of TNF-a on the BBB, brain edema, white blood cell infiltration,
and necrosis (Olsson, 1995; Ross et al., 1994). On the other hand, it
has been reported that higher TNF-a levels in the secondary step
after a TBI are beneficial because it increases NGF (Lenzlinger
et al., 2001; Scherbel et al., 1999), thus estrogen probably has
protective effects in the secondary step mediated by increased
levels of TNF-a.
The TBI we induced caused a 30% increase in TNF-a levels 6 h
later and a 50% decrease of this cytokine 24 h later. There were no
significant differences in the levels of this cytokine at the different
times after the TBI. Increasing TNF-a following a TBI has been
reported to be a brain parenchyma response to the injury (Rost-
worowski et al., 1997).
It can be proposed that a high dose of progesterone in the acute
primary step of the injury decrease TNF-a levels by decreasing IL-6
levels. The decreasing effects of progesterone on TNF-a in the
primary step (Das et al., 2002) and increasing effects of estrogen
and ineffectiveness of progesterone in the secondary step of the
injury have been confirmed by other studies (Gibson et al., 2005;
Houdeau et al., 2007; Jones et al., 2005a). Nevertheless, there are
some differences between the results of our work and that of other
researchers (Houdeau et al., 2007; Hrekova et al., 2002; Jain et al.,
2004; Yuan et al., 2002).
Brain TGF-b levels after a TBI
A low dose of estrogen in the primary step of the acute phase of
the injury caused elevated TGF-b levels. In the secondary step, both
doses of the hormones increased TGF-b levels, but the potency of
estrogen was greater than that of progesterone. Despite increasing
TGF-b levels in the acute phase of the TBI, estrogen caused an
additional enhancement of TGF-b levels. Since the anti-inflam-
matory effects of TGF-b are predominant over its inflammatory
effect, one the anti- inflammatory mechanisms of sex steroids may
be increasing TGF-b levels. A number of studies have described the
effects of estrogen and progesterone on TGF-b levels (Gibson et al.,
2005; Hatthachote and Gillespie, 1999). These hormones possibly
increase TGF-b levels via an IL-1b pathway (Hoffman et al., 2006)
and cytokines released from the brain and blood cells to prevent
BBB damage (Lenzlinger et al., 2001). TBI increases TGF-b by
nearly 250% within 6 h of the injury, but this effect has dissipated
by 24 h after a TBI. Higher TGF-( levels occur during the first day
of injury, ( Jonsson, 2007; Shifren et al., 2008). TGF-b inhibits the
production of IL-1b, TNF-a, and oxygen free radicals, which
possibly exerts anti-inflammatory effects (Chiaretti et al., 2008). A
biphasic pattern of TGF-b following trauma has been reported by
Rimaniol et. al. (Rimaniol et al., 1995). There is also a report that
shows an increase in TGF-b levels during the chronic phase of brain
trauma (McIntosh et al., 1998).
Overall, the present study showed that at 6 h after TBI estrogen
and progesterone increased IL-1b and TGF-b (only estrogen) lev-
els, whereas progesterone decreased IL-6 and TNF-a levels. This
may provide a mechanism by which evidence that treatment with
these hormones should be conducted after a brain injury. It was also
shown that sex steroids are effective in the primary step, and es-
trogen itself in the secondary step decreased IL-1b and IL-6 levels
and increased TNF-a and TGF-b levels. Progesterone in the sec-
ondary step also decreased IL-6 and increased TGF-b levels. It
seems that estrogen, mostly in the primary step, and progesterone,
in the secondary step, regulate brain cytokine expression. Fur-
thermore, these effects depend on the dose of the hormone used.
Moreover, our results suggest that reduced levels of proin-
flammatory cytokines is one mechanism for the possible anti-
inflammatory effects of sex hormones. However, other mechanisms
may be involved in the neuroprotective effects of these hormones.
In future studies we will further investigate the mechanisms by
which sex steroids and proinflammatory cytokines interact in TBI.
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